In my last article concerning Solta Medical Devices (SLTM), I remarked several times how I feel the company has good assets and the potential to grab significant market share in various segments. However, I do feel the company and its…
Written by Scott Matusow, Mr.Matusow holds a position in the company featured in this article. Last week, Cubist Pharmaceuticals Inc. (CBST) agreed to buy Trius Therapeutics Inc. (TSRX) and Optimer Pharmaceuticals Inc. (OPTR) for as much as $1.62 billion. Cubist…
Hi everyone, Scotty here with ya! In this video, I give my view on recent market action, my short/mid/long term forecast moving forward, Biotech stock commentary, and a preview of 2 picks from stockmatusow.com for next week. Premium members get…
In my opinion, investors need to be careful of the current MNKD stock run up. It’s likely it’s manipulation being pulled off by the warrant holders in order for them to cash out with good profit. Company has ZERO chance…
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
Above, we can see an historical chart of The Dow going back to 2003. Take note of the current market trend and compare to past trends. I feel the market needs a correction and is over extended on the QE…
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
